{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56","upperLimit":"94","value":"80"}]}],"title":"MYD88/L265P mutation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"25","value":"5"}]}],"title":"CXCR4/C1013G mutation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The PTEN mutation rate is the percentage of patients with PTEN mutation identified in pre-therapy and post-therapy bone marrow samples per established methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination of everolimus \\& rituximab with bortezomib for 6 cycles\n\nEverolimus 10 mg: Taken orally on a daily basis x 28 days (1 cycle)\n\nRituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only (1 cycle = 28 days)\n\nBortezomib 1.6 mg/m\\^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"The correlative objective for the study was to identify molecular regulators of response/resistance. Because the study terminated early with limited efficacy shown in the stage 1 cohort correlative objectives could not be met. Bone marrow and peripheral blood samples were collected pre- and post-therapy for phase II patients but only a few experiments conducted considering resources and the limited potential interpretation.","reportingStatus":"POSTED","timeFrame":"Samples were collected pre-therapy before the beginning therapy (baseline) and post-therapy after finishing the 6th treatment cycle (168 days).","title":"PTEN Mutation Rate [Phase II]","type":"SECONDARY","unitOfMeasure":"percentage of participants"}